Kadcyla 100mg Injection

About

Trastuzumab emtansine (T-DM1), marketed as Kadcyla, is an antibody-drug conjugate (ADC) that combines the targeted delivery of trastuzumab with the potent cytotoxic activity of emtansine (DM1), a microtubule inhibitor. Trastuzumab specifically binds to the HER2 receptor, which is overexpressed in certain breast cancers. Upon binding, the ADC is internalized by the cancer cell, where DM1 is released, leading to cell cycle arrest and apoptosis. This mechanism allows for the selective delivery of chemotherapy to HER2-positive cancer cells, minimizing systemic exposure to the cytotoxic agent and reducing side effects compared to conventional chemotherapy.

Kadcyla is primarily indicated for the treatment of HER2-positive metastatic breast cancer in patients who have previously received trastuzumab and a taxane. It represents a sophisticated approach to cancer therapy, leveraging the specificity of monoclonal antibodies to enhance the therapeutic index of chemotherapy.

Uses

• Treatment of HER2-positive metastatic breast cancer.
• Management of advanced HER2-positive breast cancer after prior therapy.
• Targeted therapy for tumors overexpressing the HER2 receptor.
• Used in patients who have progressed on trastuzumab and a taxane.

Directions For Use

This medication is administered intravenously by a healthcare professional. The dosage and schedule are determined by your doctor based on your specific condition.

Benefits

• Delivers chemotherapy directly to HER2-positive cancer cells.
• Improves progression-free and overall survival in metastatic breast cancer.
• Reduces systemic toxicity compared to traditional chemotherapy.
• Offers a targeted treatment option for resistant HER2-positive disease.
• Combines the benefits of targeted therapy and chemotherapy.
• Provides a significant treatment option for patients with limited alternatives.

Side Effects

• Fatigue
• Nausea
• Musculoskeletal pain
• Thrombocytopenia (low platelet count)
• Elevated transaminases (liver enzymes)
• Headache
• Constipation
• Diarrhea
• Peripheral neuropathy
• Vomiting
• Fever
• Infusion-related reactions

Safety Measures

• Alcohol - No specific interaction with alcohol is documented, but it's generally prudent to avoid or limit alcohol during cancer treatment.
• Pregnancy - Trastuzumab emtansine is contraindicated during pregnancy due to potential fetal harm. Women of childbearing potential must use effective contraception.
• Breastfeeding - Breastfeeding is not recommended during treatment with trastuzumab emtansine and for a period after the last dose, due to potential excretion into breast milk.
• Liver - Monitor liver function tests closely. Severe hepatotoxicity, including hepatic failure, has been reported. Dose adjustments or discontinuation may be necessary.
• Kidney - No specific dose adjustment is typically required for mild to moderate renal impairment, but caution is advised, and renal function should be monitored.
• Lung - Monitor for signs of interstitial lung disease (ILD) or pneumonitis, which can be severe and potentially fatal. Prompt evaluation is required for new or worsening respiratory symptoms.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.